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Natural killer T (NKT) cells, a unique subgroup of lymphocytes with features of both
T and natural killer (NK) cells, represent a bridge between innate and adaptive
immunity. They have the ability to either promote or suppress immune responses. With
these immunoregulatory functions, NKT cells have emerged as an important subset of
lymphocytes with a protective role in some disorders, such as infections, cancer, and
possibly sarcoidosis, and a pathogenic role in others, such as asthma, chronic obstructive
pulmonary disease and hypersensitivity pneumonitis. Immunotherapeutic interventions to
modulate the immune response by targeting iNKT cell functions has become a challenging
ﬁeld and has shown promising results for the development of new therapies.
© 2011 Elsevier Ltd. All rights reserved.
NKT cell heterogeneity
Natural killer T (NKT) cells and NKT-like cells comprise a
unique, yet highly heterogeneous subgroup of lymphocytes
that express features of both T cells and natural killer
(NK) cells and coexpress T-cell receptors (TCRs) together
with markers associated with NK cells, such as CD56 and/or
CD161.1–3 These cells are phenotypically and functionally
highly diverse, but all are hybrid by nature and represent
a bridge between innate and adaptive immunity (Table 1).
Along with macrophages, dendritic cells, and others, NK
cells are part of the innate immune system, whereas the
acquired immune system is deﬁned by the clonal expansion
of antigen-speciﬁc T and B cells and their memory immune
responses. Because NKT and NKT-like cells are part of both
systems, their absence, depletion, or improper function
affects both innate and acquired immunity.1–4
Type I and Type II NKT cells
In humans there are two major subsets of NKT cells that are
dependent on the presentation of the antigen through CD1d,
a nonpolymorphic class I antigen-presenting molecule. CD1d
is expressed on many different cells, including dendritic
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cells, thymocytes, B cells, monocytes, and macrophages.
When glycolipid antigen binds to CD1d, the antigen/CD1d
complex binds to the TCR of NKT cells.2,5 The most widely
studied are CD1d-dependent cells, which express a highly
restricted TCR with an invariant Va24-Ja18 preferentially
paired with Vb11. These are called invariant NKT (iNKT) cells
or type I NKT cells.1,2,4,6 The best-known iNKT cell antigen
is the glycolipid a-galactosylceramide (a-GalCer), originally
isolated from the marine sponge Agelas mauritianus,
which is also used to identify cells as a-GalCer-loaded
CD1d tetramers.1,7 Other glycolipid antigens for iNKT
cells have been identiﬁed, including bacterial glycolipids
such as a-galacturonosylceramide, a-glucuronosylceramide,
and a-galactosyl-diacylglycerol, as well as mammalian
glycolipids such as isoglobotrihexosylceramide (iGb3) and
the disialoganglioside GD3.2,8,9 Activated iNKT cells rapidly
release large amounts of both T-helper 1 (TH1), TH2, and/or
TH17-speciﬁc cytokines and exhibit both antigen-speciﬁc
and NK-like cytolytic activities.1,2,5,10 Invariant NKT cells
are therefore able to both promote and suppress immune
responses, presumably due to the existence of many distinct
subsets with different functions.2,3,8 Among these, CD4+ iNKT
cells produce both TH1 (such as interferon-g (IFN-g) and
tumor necrosis factor a (TNF-a)) and TH2 cytokines (such
as interleukin-4 (IL-4), IL-10, and IL-13), and are associated
with TH0-type immune responses, whereas CD4–CD8– and
CD4–CD8+ iNKT cells are similar and mainly produce TH1
cytokines.1,2,11,12 Furthermore, a subset of iNKT cells that
produces high amounts of cytokine IL-17 was recently
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Table 1
Classiﬁcation of NKT and NKT-like cells
Invariant NKT cells
Type I NKT cells
Classical NKT cells
Type II NKT cells
Non-classical NKT cells
NKT-like cells
Antigen presentation CD1d CD1d MHC










NKT and NKT-like cells in pulmonary disorders
Disorder Finding
Asthma Altered numbers of iNKT cells (inconsistent results)
COPD Increased numbers of iNKT and CD3+CD56+ NKT-like cells in lungs, deﬁciency
of CD3+CD56+ NKT-like cells in peripheral blood
Sarcoidosis Deﬁciency of iNKT cells
Hypersensitivity pneumonitis Increased numbers of CD3+CD16/CD56+ NKT-like cells, normal numbers of
iNKT cells
Lung cancer Deﬁciency and impaired function of iNKT cells
Tuberculosis Deﬁciency of iNKT cells in active phase
identiﬁed.2,12–14 These iNKT cells are CD4–NK1.1–, which
distinguishes them from the majority of other NKT cells and
may have an important role in IL-17-mediated disease.2,13
The second group of CD1d-dependent cells, called
also type II NKT cells, expresses an unbiased TCR
repertoire and recognizes several hydrophobic antigens
such as sulfatide, lysophosphatidylcholine, and aromatic
molecules.2,15,16 These cells have been less thoroughly
studied, mainly because they cannot be identiﬁed using
a-GalCer-loaded CD1d tetramers. They are not discussed
further in this review.
NKT-like cells
The third group that resembles NKT cells, and is often
referred to as NKT cells, are so-called NKT-like cells, or
CD1d-independent T cells. These cells are independent of
CD1d for their activity,3,6,10 and so they depend on the
presentation of antigen to conventional MHC class I and
II molecules and express unbiased a/b T-cell receptors.
Other than the expression of CD161 and/or CD56, there
is little evidence that these NKT-like cells are related to
NKT cells.3,17 NKT-like cells comprise a highly heterogeneous
group of cells, being either CD4+, CD8+, or double-negative
CD4–CD8– T cells that also express NK-cell markers such as
CD161 and/or CD56.3
Role of NKT cells in various disorders
The roles of different subsets of NKT cells in humans
are not completely understood, but it is well established
that many have immunosuppressive activity and/or may
promote enhanced cell-mediated immunity.18,19 NKT cells
have been implicated in several biological processes,
including cell-mediated suppression of tissue destruction,
anti-tumor responses, autoimmunity, host defense, allergy,
and inﬂammation, as well as direct inﬂuences on B-cell
proliferation and antibody production.1–3,20,21 Their role
has mainly been associated with priming and regulating
the immune response because numerical and/or functional
impairments have been reported in many pulmonary
disorders. Thus, NKT and NKT-like cells might play a critical
role in several pulmonary diseases, including asthma,
chronic obstructive pulmonary disease (COPD), interstitial
lung diseases such as sarcoidosis and hypersensitivity
pneumonitis (HP), lung cancer, and infectious diseases such
as tuberculosis (Table 2).1–3
Asthma
Invariant NKT cells produce large amounts of both TH1
and TH2 cytokines and may either inhibit or exacerbate
allergic response. Because asthma is characterized by a
highly polarized TH2 immune response, tissue inﬂammation,
and airway hyperreactivity, various immune system cells,
including NKT cells, have important roles in it. However, the
reported results regarding the contribution of iNKT cells in
asthma have been controversial. Early reports demonstrated
an increased number of iNKT cells in the lungs of patients
with asthma compared to patients with sarcoidosis and
healthy controls.22–24 However, in subsequent years these
ﬁndings were challenged by other groups, who reported
lower iNKT cell counts than previously reported.25,26 Recent
publications have highlighted the role of iNKT cells in asthma
because several studies have shown a signiﬁcant increase
of iNKT cells in patients with asthma.27,28 Furthermore, it
has been demonstrated that iNKT cells play an important
role in the development of airway hyperreactivity and
airway inﬂammation in mice and nonhuman primates,22,27 in
which several environmental substances, including bacterial
glycolipids, were shown to activate iNKT cells.29 It is
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now becoming evident that iNKT cells are involved in the
pathogenesis of asthma because they might be employed as
effectors as well as ampliﬁers of TH2 cell response.30,31
Chronic obstructive pulmonary disease
COPD is a disease consisting of emphysema, respiratory
bronchiolitis and chronic bronchitis that is largely driven
by TH1-mediated immune responses.32,33 Increased levels of
iNKT cells were found in the lung tissue of patients with
COPD. Furthermore, interactions of CD4– iNKT cells with
macrophages, subsequent activation and IL-13 production
appears to be crucial for the development of chronic airway
disease in animal mouse model.34 Beside that increased
numbers as well as enhanced cytotoxicity of CD3+CD56+
NKT-like cells in the induced sputum of COPD patients was
observed, what is in contrary to what was observed in the
peripheral blood. Therefore, those cells could be selectively
recruited to the lungs.35,36 Furthermore, the proportion of
CD8+ NKT-like cells was increased and CD4+ NKT-like cells
were decreased in COPD patients. Therefore, CD8+ NKT-
like cells with the production of predominantly TH1-type
cytokines could be responsible for the pro-inﬂammatory
immune response in the lungs of COPD patients.36
Sarcoidosis
Sarcoidosis is a multi-system disorder of unknown etiology
that predominantly involves the lungs and is characterized
by TH1-biased CD4+ T cell response and the formation of
granulomas. Other than evidence of T-cell involvement
in the characteristic immune response, it is still unclear
how this response is generated. The immunoregulatory
properties of iNKT cells may play a very important role
in sarcoidosis because loss of immunoregulation due to
a deﬁciency and/or impaired function of these cells
might contribute to the ampliﬁed and prolonged T-cell
activity that characterizes sarcoidosis.37–40 Deﬁciencies of
iNKT cells in the blood and bronchoalveolar lavage ﬂuid
(BALF) of sarcoidosis patients have been reported.37,38,40
The data on granulomas are inconsistent because there
are reports on both the absence of iNKT cells in
granulomatous38 and cutaneous lesions41 and also the
accumulation of iNKT cells in granulomatous lesions of
sarcoidosis patients.37 Furthermore, stimulated peripheral
blood iNKT cells from sarcoidosis patients demonstrated
impaired IFN-g production.37 A low number of iNKT cells
and impaired IFN-g production might be involved in the
inﬂammatory process in sarcoidosis and disease progression
because the involvement of IFN-g in granuloma formation is
well documented.37,39 However, longitudinal analysis of iNKT
cell frequency and/or function throughout the course of the
disease is needed to elucidate the exact role of these cells
in the pathogenesis of sarcoidosis.
Hypersensitivity pneumonitis
A recent study showed signiﬁcantly higher CD3+CD16/56+
NKT-like cell frequencies in the BALF of patients with
HP compared to study cases with other interstitial lung
diseases.42 Therefore, assessing the CD3+CD16/56+ cells in
the BALF might be a helpful adjunct in the diagnosis of
HP. It was further demonstrated that a large proportion
of the BALF cells of HP patients were of the CD8+CD56+
subset, and the majority of these cells did not express the
invariant Va24 T-cell receptor or CD161. Wajchman et al.
showed that this distinct CD8+CD56+CD161– cell phenotype
displays both antigen-speciﬁc (CTL-like) as well as NK-like
cytolytic activities that are independent of HLA class I and
CD1 molecules.10 Pittet et al. demonstrated that the potent
cytolytic effector function of these cells closely correlates
with CD56 surface expression and that these cells contain
high amounts of intracellular perforin and granzyme B.43
The frequencies of iNKT cells in the BALF of HP patients were
comparable to those in the BALF of healthy control subjects,
and thus iNKT cells are unlikely to play an important role in
the pathogenesis of HP.25,26,40
The increased number of CD8+CD56+ cells in the BALF
of HP patients is interesting from several points of
view. First, animal models suggest that hypersensitivity
pneumonitis is characterized by a TH1-type response44 and
that IFN-g is necessary for the development of disease
because IFN-g knockout mice are resistant to developing
hypersensitivity pneumonitis.45 Exposure to IL-12 further
enhanced IFN-g production and consequently modulated
the severity of experimental hypersensitivity pneumonitis.46
Yamasaki et al. demonstrated that clinical hypersensitivity
pneumonitis is also characterized by a TH1-type response
and the predominance of IFN-g producing T cells.47
Therefore, the potential importance of NKT-like cells in
hypersensitivity pneumonitis is strengthened by the ﬁndings
that CD8+CD56+ cells are more potent inducers of TH1-
mediated immune response relative to CD8+ T cells and
that the IL-12 stimulated CD8+CD56+ cells can produce much
larger amounts of IFN-g than CD8+ T cells.48 Second, the
CD8+CD56+ cells also have a unique chemokine receptor
repertoire and a functional migratory response to the CCR5
ligand macrophage inﬂammatory protein-1 beta (MIP-1b).49
MIP-1b can markedly affect the mononuclear inﬁltration
of the lung and was speciﬁcally detected in the BALF
of HP patients compared to patients with sarcoidosis and
cryptogenic ﬁbrosing alveolitis.50
Lung cancer
The pro-inﬂammatory activities of iNKT cells are important
for the anti-tumor response in lung cancer. In particular,
this includes the ability to induce secondary immune
effects by producing INF-g and subsequently activating the
conventional CD8+ T cells and NK cells.51,52 In addition,
the perforin-dependent direct cytotoxicity of activated iNKT
cells is also important.53 Compound action by NKT and
NK cells is important for natural anti-tumor immunity.51–53
Decreased numbers and reduced functions of iNKT cells
have been reported in peripheral blood of cancer patients
as well as in tumor tissues.1,51,54 Furthermore, iNKT cells
from cancer patients have been shown to have defective
cytokine production because they produce less IFN-g than
do iNKT cells from healthy individuals.54,55 Activation of iNKT
cells also shows promising results in cancer immunotherapy.
Administration of a-GalCer and the subsequent activation of
iNKT, as well as treatment with in vitro-activated iNKT cells,
have demonstrated clear clinical beneﬁts in lung cancer.
The therapy was well tolerated and induced an iNKT cell-
modulated immune response, prolonging survival time in
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non-small cell lung cancer patients.56–58 Seventeen patients
with advanced non-small cell lung cancer refractory to
the standard therapy, were treated with a-GalCer-pulsed
autologous PBMCs. Ten patients who displayed increased
IFN-g-producing cells showed signiﬁcant prolongation of
estimated median survival time (31.9 months; range, 14.5
to 36.3 months) as compared with poor-responder patients
(9.7 months; range, 3.8 to 25.0 months).58
Infectious diseases: tuberculosis
iNKT cells are able to exhibit both pro-inﬂammatory and
anti-inﬂammatory properties; they have been implicated
in bacterial, viral, fungal, protozoan, and helminthic
infections. The immune response to microorganisms can
be generated through iNKT cells’ recognition of glycolipid
antigens present in pathogens or by indirect activation of
iNKT cells in the presence of inﬂammatory cytokines against
microorganisms that do not contain iNKT cell antigens.29,59
There is growing evidence that iNKT cell deﬁciency might
be crucial for the development of active tuberculosis in
patients infected with Mycobacterium tuberculosis because
not only was iNKT cell deﬁciency associated with the active
phase of the disease, but normal cell frequencies were also
restored by treatment.1,60–62 However, further investigations
are needed to determine the exact role of iNKT cells
in tuberculosis, in addition to determining which subsets
and antigens are responsible for activating iNKT cells and
which speciﬁc cytokines are secreted during the course of
disease.1,29
Therapeutic potential
Immunotherapeutic interventions for the modulation of
immune response by targeting immunoregulatory functions
of iNKT cells has become a challenging ﬁeld because it is
established that these cells might play an important role
in a wide range of disorders, including cancer, autoimmune
diseases, and infections. Immunotherapeutic approaches
targeting iNKT cells should restore proper immune system
balance because various subsets and conditions of iNKT
cells can either suppress or promote immune responses.1,4,21
Activation of iNKT cells by a-GalCer or its analogues
has shown promising results in cancer therapy. Activated
iNKT cells induced anti-tumor activities of other immune
system subsets, such as B and CD8+ T cells. Therefore,
administration of a-GalCer dendritic cells pulsed with
a-GalCer or in vitro-activated iNKT cells are plausible novel
cancer immunotherapies.56–58 Incorporation of glycolipids
that activate iNKT cells, such as a-GalCer or its analogues,
into the vaccine would allow us to tailor the immune
response to it because it is known that iNKT cells can
act as direct effector cells, and may modulate both
adaptive and innate immunity.1,29 On the other hand,
inhibition or blockade of iNKT with anti-CD1d antibodies, or
especially a CD1d-dependent antagonist of iNKT cells such
as dipalmitoyl-phosphatidyl ethanolamine (DPPE), protected
against allergen-induced airway hyperreactivity in a mouse
model, demonstrating possible clinical use in treating
allergic asthma.63 The ability to speciﬁcally manipulate
iNKT cells raises new possibilities for immunotherapeutic
interventions in other diseases in which these cells play
important roles, including infections and autoimmune
diseases.
Conclusions
NKT cells represent a bridge between innate and adaptive
immunity. With their immunoregulatory functions, they
have emerged as an important subset of lymphocytes with
a protective role in some diseases, such as infections,
cancer, and possibly sarcoidosis, and a pathogenic role in
others, such as asthma. Modulation of the immunoregulatory
functions of these cells has shown promising results for the
development of new therapies.
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